BETHESDA, Md., May 3, 2013 — Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for solid tumor
cancers, announced today the availability on the web of several
interviews of their CEO Linda Powers on the floor of the New York
Stock Exchange on May 1, 2013 by FOX Business News (FOX), the
Huffington Post, and the International Business Times, amongst
others.

In the FOX interview, Ms. Powers described the importance of NW
Bio’s DCVax technology in mobilizing a patient’s whole immune
system, and in targeting the full set of biomarkers on the
cancer. This way, the DCVax treatment involves many active
agents hitting many targets on the cancer, rather than just a
single active agent hitting a single target, as is typical with
cancer drugs and some other types of immune therapies. Ms.
Powers explained that NW Bio’s approach makes it harder for the
tumor to “escape,” which the Company believes is responsible for
the striking results in clinical trials so far, adding years of
survival in patients (rather than weeks or months) and doing so
without toxicity. These results are clearly differentiating NW
Bio from other players in this burgeoning field.

You can see the FOX interview at
http://video.foxbusiness.com/v/2344168115001/latest-advances-in-cancer-research/

In the Huffington Post and New York Financial Press interview,
Ms. Powers outlined in more detail the process for combining the
tumor tissue biomarkers with the dendritic cells (master immune
cells), obtained through a blood draw from the patient, to create
the vaccine.  Additionally, she stressed the significance of
key regulatory approvals obtained in the US and Europe, relating to
Phase III clinical trials and Phase I/II trials for both operable
and inoperable tumors that provide NW Bio with multiple
opportunities for success.

You can view the Huffington Post interview at
http://videos.huffingtonpost.com/business/nw-biotherapeutic-challenges-cancer-with-dc-vax-517764763 

In the International Business Times interview, Ms. Powers
recounted the cost saving potential of the DCVax platform, which
positions NW Bio well in the face of the rapidly rising costs of
less effective conventional cancer treatments.  Ms. Powers
explained the two main versions of the NW Bio vaccines, for
operable and inoperable tumors, in all solid tumor cancers (cancers
in any tissues of the body), as well as the ultimate power of the
immune system and the consistent, positive results obtained in
clinical trials to date with DCVax treatments for several diverse
types of cancers.

You can view the International Business Times interview at
http://tv.ibtimes.com/vaccine-cure-cancer-new-breakthrough-cancer-treatments-northwest-biotherapeutics-10585#share

These periodic interviews are another in a series of continuing
initiatives to inform the financial and medical communities about
NW Bio’s progress.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both the
U.S. and Europe. The Company has a broad platform technology for
DCVax dendritic cell-based vaccines. The Company’s lead program is
a 312-patient Phase III trial in newly diagnosed Glioblastoma
multiforme (GBM). GBM is the most aggressive and lethal brain
cancer.  The Company also previously received clearance from
the FDA for a 612-patient Phase III trial in prostate cancer, and
clearance from the FDA for Phase I/II trials in multiple other
cancers. The Company has also conducted a Phase I/II trial with
DCVax for metastatic ovarian cancer together with the University of
Pennsylvania.

Disclaimer

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “expect,” “believe,” “intend,”
“plan,” “continue,” “may,” “will,” “anticipate,” and similar
expressions are intended to identify forward-looking statements.
Actual results may differ materially from those projected in any
forward-looking statement. Specifically, there are a number of
important factors that could cause actual results to differ
materially from those anticipated, such as the Company’s ability to
raise additional capital, risks related to the Company’s ability to
enroll patients in its clinical trials and complete the trials on a
timely basis, the uncertainty of the clinical trials process,
uncertainties about the timely performance of third parties, and
whether the Company’s products will demonstrate safety and
efficacy. Additional information on these and other factors,
including Risk Factors, which could affect the Company’s results,
is included in its Securities and Exchange Commission (“SEC”)
filings. Finally, there may be other factors not mentioned above or
included in the Company’s SEC filings that may cause actual results
to differ materially from those projected in any forward-looking
statement. You should not place undue reliance on any
forward-looking statements. The Company assumes no obligation to
update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.